We previously reported that S100B, a 20kDa Ca 2+ -binding homodimer, inhibited the post-infarct myocardial hypertrophic response mediated by α 1 -adrenergic stimulation through the protein kinase C (PKC) signaling pathway. In the present study, we examined whether the same pathway induced the S100B gene, supporting the hypothesis that S100B is a feedback negative regulator of this pathway. We transfected cultured neonatal rat cardiac myocytes with a luciferase reporter gene driven by the maximal human S100B promoter and progressively shorter segments of this promoter sequentially deleted from the 5' end. We identified a basic promoter essential for transcription spanning 162 bp upstream of the transcription initiation site and positive (at -782/-162
INTRODUCTION
Myocardial infarction, the leading cause of death in the developed world, results in an acute loss of functional myocardium. Among survivors, post-infarct ventricular remodeling is an adaptive response of the heart to this loss in an attempt to preserve cardiac performance (25) . Myocardial hypertrophy is an integral component of this adaptive response. Because adult cardiac myocytes are terminally differentiated and have lost the ability to divide, this increase in mass is due to enlargement of individual myocytes. The hypertrophic response can be reproduced in rat and mouse experimental models and cultured neonatal cardiac myocytes from these species (5, 25, 26) .
Experimental work in these models has implicated hormonal stimulation including α 1 -adrenergic agonists and angiotensin II (AII), peptide growth factors, and mechanical stretch as instigators of the hypertrophic response (4, 30, 35) . Some of these, including α 1 -adrenergic agonists, activate the PKC signaling pathway (14, 17) . Furthermore, in addition to growth, myocytes have been shown to respond to trophic stimuli in these models by re-expression of several fetal genes including the embryonic β-myosin heavy chain (β-MHC), the skeletal isoform of α-actin (skACT), and atrial natriuretic factor (ANF) (4, 14, 17, 35) .
The relative contributions of the various trophic stimuli that initiate and sustain the hypertrophic response after myocardial infarction have not been defined. Moreover, some form of negative regulation may be involved to limit unchecked hypertrophy. We have previously proposed that S100B, a 20kDa Ca 2+ -binding homodimer, normally expressed in brain astrocytes, was a candidate for an intrinsic negative regulator of the myocardial hypertrophic response based on the following experimental observations.
First, while S100B is normally not expressed in the myocardium, S100B protein was identified immunohistochemically in the peri-infarct region of the human heart following myocardial infarction and S100B mRNA was detected in rat heart after coronary artery ligation in an experimental model of myocardial infarction (32, 33) . Second, in cotransfection experiments in cultured neonatal rat cardiac myocytes, S100B inhibited the α 1 -adrenergic-mediated induction of β-MHC and skACT through the PKC signaling pathway (32) . Third, in S100B-overexpressing transgenic mice, S100B protein and mRNA were detected in the heart following α 1 -adrenergic agonist infusion, and the hypertrophic response, normally evoked in the heart and cultured myocytes in response to α 1 -adrenergic stimulation in wild-type mice, was abrogated (33) .
The above data suggest that S100B functions as a negative feedback regulator of the α 1 -adrenergic-mediated component of the hypertrophic response following myocardial infarction. A corollary of this suggestion is that the S100B gene is induced after myocardial infarction by the same α 1 -adrenergic pathway. In order to formally examine this possibility, we used luciferase reporter constructs to study the activation of the human S100B promoter by components of the α 1 -adrenergic signaling pathway in cultured rat myocytes. These components included PKC, and the transcription factors, transcription enhancer factor-1 (TEF-1) and related TEF-1 (RTEF-1) that bind to MCAT elements. These elements have previously been reported to be involved in the induction of the fetal genes β-MHC and skACT in cultured rat neonatal cardiac myocytes and in intact rat heart (15, 16, 17, 19, 31) . We report the specific induction of the S100B
promoter by α 1 -adrenergic stimulation in rat myocytes through the PKC signaling pathway, and the selective modulation of this induction by TEF-1 and RTEF-1 acting through MCAT elements in the S100B promoter.
MATERIALS AND METHODS
Human S100B promoter driven reporter plasmids. A luciferase reporter gene system (Promega, Madison, WI) was used to study the relative ability of different 5'
DNA regions of the human S100B gene to promote transcription in transient transfection assays, as previously described (3) . In this system, a maximal human S100B promoter and progressively shorter fragments sequentially deleted from the 5' end of the maximal promoter by restriction enzyme digestion were cloned upstream of the luciferase gene into the plasmid pGL3 that lacks eukaryotic enhancer and promoter sequences. Initially, a 9.8 kb Hind III fragment of human genomic DNA (1), spanning exons 1 and 2 (and the intervening intron) of the human S100B gene, and 6689 bp of upstream and 320 bp of downstream DNA sequence, numbered in accordance with the human S100B genomic sequence in the National Center for Biotechnology Information (NCBI) database, was subcloned into a Bluescript (pBS) plasmid (Stratagene, La Jolla, CA) to generate pBS100 9.1. A HindIII/Bam HI fragment spanning the DNA nucleotide sequence -6689/+698
relative to the transcription initiation site was excised from pBS100 9.1, and designated as the maximal S100B promoter. This fragment includes 6689 bp of DNA sequence upstream of exon 1, exon 1 (71 bp) and 627 bp of downstream sequence and was subcloned into pGL3 to generate pGBS -6689/+698. The reporter plasmids containing progressively shorter segments of the maximal promoter were generated by subcloning the fragments KpnI/BamHI, PvuII/BamHI, and SmaI/BamHI, excised from pBS100 9.1, into pGL3 to generate pGBS -4463/+698, pGBS -782/+698, and pGBS -162/+698, respectively (3). The plasmid pGBS ∆162/+698 was generated similarly from a fragment created by deleting the region -162/+698 from pGBS -4463/+698 (see Fig. 3 ).
Expression plasmids. The following expression plasmids were obtained from the indicated sources: SRα-∆PKCβ (containing a partially deleted constitutively active βPKC cDNA driven by a SV40 early promoter) from Dr. P.C. Simpson (14) ; pXJ40- 4101 or 0.01% DMSO for staurosporine, nifedipine, A23187, and PMA) for 48 h. The cell lysates were assayed for luciferase (LUX) and CAT activity using published techniques (7, 11) . Co-transfection with any of the plasmids or treatment of cultures as described above did not affect CAT activity. The differences of the respective LUX and CAT activities between duplicate dishes were <10% of their mean. LUX activity was normalized for transfection efficiency on the basis of CAT activity in the same dish.
Treated/control ratios were tested from deviation from unity by calculation of confidence limits.
Ribonuclease protection assay. RNA was isolated from i) cultured rat neonatal myocytes and fibroblasts, ii) rat tissues, including fetal, neonatal , and adult heart and brain and iii) residual non-infarcted rat left ventricular myocardium outside the territory supplied by the ligated coronary artery (32) , by a one-step guanidine thiocyanate/phenol method (6) . RNase protection assays to determine steady-state levels of S100B and glyceraldehyde-3 phosphate dehydrogenase (GAPDH) mRNAs were performed as previously described (32) .
Detection of human S100B mRNA by RT-PCR. RNA was isolated from myocyte cultures, human and rat brain by a one-step guanidine thiocyanate/phenol method (6) on the S100B promoter in Fig. 7A . Nuclear extracts from cardiac myocytes were prepared as described previously (15) . Binding reactions were performed as described (15, 16, 17) .
Statistical analysis.
Treated/control ratios were tested for deviation from unity by calculation of confidence limits. Mean values were compared by analysis of variance by the Student-Newman-Keuls test, with significance defined as p<0.05.
RESULTS

S100B exhibits no basal expression in cultured neonatal rat cardiac myocytes or
fibroblasts but is present in residual rat myocardium adjacent to myocardial infarction.
Steady-state levels of S100B and GAPDH mRNAs were determined using an RNase protection assay in cultured rat neonatal cardiac myocytes and fibroblasts, and in fetal, neonatal, and adult rat heart and brain, as well as in non-infarcted adult myocardium adjacent to an infarct resulting from coronary artery ligation (Fig. 1) . S100B mRNA was not detected in cultured neonatal myocytes or fibroblasts, nor in fetal, neonatal, or adult heart, or in fetal or neonatal brain, but was highly expressed in adult brain. Following coronary artery ligation, S100B mRNA was expressed in the peri-infarct region of the adult myocardium (35 days post-infarction) at levels equivalent to those seen in adult brain. The constant amounts of GAPDH mRNA in all samples served as controls for the quality of the RNA and confirmed equal loading in all lanes.
Coronary artery ligation is associated with increased levels of norepinephrine. Thirtyfive days post coronary artery ligation, increased norepinephrine levels were seen in periinfarct region of the adult myocardium (35 days post-infarction) compared to shamoperated animals (696+34 vs. 468+25 ng/g left ventricular tissue, respectively, p<0.05, n=6).
Expression of the exogenous human and endogenous rat S100B gene in transfected rat cardiac myocytes. Cultured neonatal rat cardiac myocytes were transfected with plasmid pW9Fc carrying 17.3kb of human genomic DNA that includes a full-length S100B gene. Human and rat S100B mRNAs were assayed by RT-PCR. The endogenous rat and human S100B mRNAs were expressed in rat and human brain, respectively ( Fig.   2A, 2B ). The endogenous rat S100B mRNA was absent from untreated rat myocyte cultures and present following treatment with the α 1 -adrenergic agonists NE and PE,
but not with the β 1 -agonist ISO or T3 ( Fig. 2A) . Similarly, the level of the human S100B mRNA derived from the transfected human S100B gene was markedly increased in cultures treated with α 1 -adrenergic agonists NE and PE from a low basal level in untreated cultures (Fig. 2B) . Treatment with the β 1 -adrenergic agonist ISO or T3 did not increase the level of human S100B mRNA above the basal level.
α 1 -adrenergic stimulation specifically activates the human S100B promoter through the PKC signaling pathway. In order to study the activation of the human S100B
promoter by hormonal stimulation, we initially cloned progressively shorter segments of the maximal human S100B promoter sequentially deleted from the 5' end in front of the luciferase reporter gene. These constructs were transfected into cultured neonatal rat cardiac myocytes. We showed that basal transcription from the various S100B promoter constructs was selective for cardiac myocytes, since it was absent in similarly transfected cultured neonatal rat fibroblasts (data not shown). We also identified a basic promoter, cloned in pGBS-162/+698 and defined as the shortest S100B promoter fragment assayed, that spanned 162 bp upstream of the transcription initiation site, 71 bp of exon 1, and 627 bp of intron 1 (Fig. 3) . The basic promoter contains several general transcription elements including a TATA box, a reverse CCAAT box, and two GC boxes (1). The relative luciferase activities of the various cloned constructs that comprised additional sequences upstream of the basic promoter were 2-fold for pGBS-782/+698, 0.5-fold for pGBS-4463/+698, and 4-fold for the maximal promoter -6689/+698, all relative to the basic promoter (Fig. 3) . This indicates the presence of positive regulatory elements in the sequences -782/-162 and -6689/-4463, and of a negative regulatory element in the sequence -4463/-782. There were no additional transcription initiation sites upstream of the basic promoter, as absence of the basic promoter from the cloned construct pGBS ∆-162/+698 abolished transcription (Fig. 3) .
In response to hormonal stimulation, transcription from the basic (cloned in pGBS-162/+698) and maximal (cloned in pGBS-6689/+698) promoters was stimulated by the α 1 -agonists NE and PE. Treatment with PE stimulated transcription 4-fold, equally from the basic and maximal promoters (Fig. 4A) . The PE response was blocked by the α 1A -adrenergic receptor antagonist WB401, but not the α 1B -adrenergic receptor antagonist CEC (Fig. 4A) . Treatment with ISO, T3, or AII did not stimulate transcription from the basic or maximal S100B promoter (Fig. 4B) . Transcription from the basic and maximal S100B promoters was also stimulated by PMA, an activator of PKC, and the stimulation of transcription by PE and PMA was blocked by the PKC antagonist staurosporine (Fig. 5A) . Neither the calcium ionophore A23187 nor the calcium channel antagonist nifedipine had any effect on basal or PE-stimulated transcription (Fig. 5A) .
Using a co-transfection strategy, we found that transcription was stimulated 2-fold, equally from both promoters, by ∆PKCβ, a constitutively active mutant of βPKC (Fig.   5A ). This stimulation was blocked by staurosporine. Furthermore, stimulation with ∆PKCβ, when combined with PE treatment, did not further increase the stimulation obtained with PE alone (Fig. 5B) . (Fig. 6A) , RTEF-1 stimulated basal transcription 1.5-2-fold and had no effect on the PE-induced transcriptional stimulation (Fig. 6B) . Co-transfection with the transcription factors Fos or
Jun, that are also distal components of the PKC signaling pathway, did not influence transcription from either the basic or maximal promoter (data not shown).
S100B MCAT elements exhibit specific binding to cardiac myocyte nuclear
extracts. Two MCAT motifs were identified in the maximal S100B promoter, MCAT1 (-1984/-1978) and MCAT2 (-1333/-1327) (Fig. 7A) . To determine if the S100B MCAT sequences bound members of the TEF-1 family, gel mobility shift assay was performed using cardiac myocyte nuclear extract and the radiolabelled -84/-61 skACT promoter containing the canonical MCAT sequence (Fig. 7B) . The results of our previous studies implicated S100B as a negative modulator of the hypertrophic response contributed by α 1 -adrenergic stimulation (32, 33) . We were able to demonstrate that S100B inhibited the induction of β-MHC and skACT through the PKC pathway in the context of the hypertrophic response induced by α 1 -adrenergic stimulation in cultured rat myocytes (32) . The present study was undertaken to examine whether the S100B gene induction in cardiac muscle was mediated by the α 1 -adrenergic pathway. This would support the hypothesis that S100B functions as a feedback regulator of this component of the hypertrophic response.
We have previously reported a de novo presence of S100B protein and mRNA in the peri-infarct region of human and rat hearts (33) . In the present study, we found that the presence of S100B mRNA in the peri-infarct region of rat heart following an experimentally provoked myocardial infarction consequent to coronary artery ligation coincided with increased left ventricular NE levels. We wished to demonstrate that the induction of steady-state S100B mRNA levels from undetectable in normal heart to a level equivalent to that seen in rat brain following myocardial infarction, was due to an induction of the S100B gene by increased NE levels. For this purpose, we first transfected cultured neonatal rat cardiac myocytes with a full-length human S100B gene and showed that both the endogenous rat S100B gene and the transfected human S100B gene were specifically induced by the α 1 -adrenergic agonists NE and PE but not the β 1 -adrenergic agonist ISO or T3.
In order to begin to dissect the functional activation of the human S100B
promoter in heart, we transfected cultured rat myocytes with constructs incorporating a luciferase reporter gene driven by the human S100B promoter. In the first instance, we used a maximal S100B promoter, spanning 6689 bp upstream of the transcription initiation site, and progressively shorter fragments sequentially deleted from the 5' end of this promoter, to define a basic promoter essential for transcription (spanning 162 bp upstream of the transcription initiation site), two positive regulatory elements (located in the regions -782/-162 and -6689/-4463), and one negative regulatory element (located in the region -4463/-782). There was no transcription from any of the S100B promoter fragments in cultured neonatal rat cardiac fibroblasts. In our previous studies, in cultured neonatal rat astrocytes, we used a similar strategy starting with a maximal promoter that spanned 4463 bp upstream of the transcription initiation site (3) . In these studies, we identified the same basic promoter, the positive regulatory element at -782/-162, and the negative regulatory element at -4463/-782. Presently, by using a longer maximal promoter as our starting point for generating the 5' deletion fragments, we extended these results by identifying an additional positive regulatory element at -6689/-4463. The similarity in the basic human S100B promoter and upstream regulatory elements identified in rat astrocytes and myocytes, and the absence of transcription in rat fibroblasts, indicate a tissue selective distribution of specific transcription factors that activate the S100B promoter and are conserved among mammalian species. This is consistent with the experimental evidence suggesting highly specialized functional roles for S100B in mammalian brain and heart (8).
We then used the basic and maximal S100B promoters to study the induction of S100B in cardiac myocytes by α 1 -adrenergic stimulation. Both promoters were activated by the α 1 -adrenergic agonists NE and PE through the α 1Α -adrenergic receptor, but not by any other hormonal myocardial trophic signals including T3, AII, or the β 1 -adrenergic agonist ISO. The activation by PE was blocked by the PKC antagonist staurosporine suggesting involvement of the PKC signaling pathway. This suggestion was supported
by showing activation of the S100B promoter by treatment with the phorbol ester PMA (that activates PKC) and by co-transfection with ∆PKCβ, a constitutively active mutant of βPKC. The activation by PMA and ∆PKCβ was also blocked by staurosporine again implicating the PKC signaling pathway. The two-fold activation seen with ∆PKCβ was approximately half of that seen with PE and the two together were not additive, suggesting that both PKCβ and other isoforms of PKC are involved in this activation consistent with previously published results (2, 28). There were no significant differences in the activation of the S100B promoter by PE in the presence or absence of either the Ca 2+ ionophore A23187 or the Ca 2+ channel blocker nifedipine, suggesting that Ca 2+ was not a likely second messenger of the α 1 -adrenergic signal leading to the activation of the S100B promoter. Taken together, the above data indicate that the same α 1 -adrenergic pathway, that initiates and sustains the hypertrophic response in cardiac myocytes by activating PKC and is subject to negative modulation by S100B, also induces the S100B gene (32) . This supports the hypothesis that S100B is a negative feedback regulator of this pathway.
While α 1 -adrenergic activation of the S100B promoter proceeded equally well with the basic and maximal promoters, the same was not the case for the transcription factors TEF-1 and RTEF-1. Both factors required the maximal promoter for their action, consistent with the presence of M-CAT sequences (CATTCCT at -1322 to -1328 and CATTCCA at -1975 to -1981) upstream of the basic promoter that exhibited specific binding activity. TEF-1 trans-repressed the maximal full-length S100B promoter both under basal conditions and in the presence of PE, preventing the previously documented α 1 -adrenergic activation of the S100B promoter. The inhibition of the S100B promoter was not seen with 10-fold and 100-fold lower concentrations of TEF-1 (data not shown).
The inhibitory effect of TEF-1 is comparable to the response of the skACT promoter and may result from TEF-1 overabundance sequestering or "squelching" a limiting co-factor (31). Conversely, RTEF-1 trans-activated the same S100B promoter 2-fold versus a 4-fold activation seen with PE, and the two together were not additive. This suggests that a component of the α 1 -adrenergic induction of the S100B promoter is mediated in part through RTEF-1. It is conceivable that this two-tiered mechanism of induction of S100B confers the following advantages. First, the RTEF-1 component provides a means to regulate the induction of the S100B gene coordinately with the induction of fetal genes such as βMHC and skACT, and second, the non-RTEF-1 component ensures an induction of the S100B gene in conditions where the amount of RTEF-1 might be limiting. Moreover, since PE alone activated the basic and maximal S100B promoters equally well, the above results also suggest that in the presence of the maximal promoter (as is the case in the physiological situation), α 1 -adrenergic stimulation of S100B is differentially modulated by TEF-1 and RTEF-1. Additional regulation may be dependent on elements present in the basic promoter, first intron, and/or upstream of the basic promoter. Candidate elements include multiple MEF-2 and GATA4 sites (Fig. 7A) , that have been reported to be targets for α 1 -adrenergic induction of the α-MHC, B-ANF, myosin light chain, and cardiac troponin C promoters (20, 22, 36) .
The opposing actions of TEF-1 and RTEF-1 on transcription from the S100B promoter are consistent with their possible opposing roles in the expression of the genetic program that underlies post-infarct myocardial hypertrophy (31) . Furthermore, the transrepression of the S100B promoter by TEF-1 may also be involved in silencing this gene in normal myocardium. Thus, the relative abundance of TEF-1 and RTEF-1, or their selective inactivation or activation, respectively, may control the induction of the S100B gene during myocardial hypertrophy. In the post-infarct setting, the initial accession and subsequent waning of the hypertrophic response are necessary for orderly ventricular remodeling (27) . This likely requires a fine balance between signaling pathways such as 
